Cataracts: Lens changes have been observed in patients during long-term quetiapine treatment.Leukopenia, Neutropenia and Agranulocytosis: Monitor complete blood count frequently during the first few months of treatment in patients with a pre-existing low white cell count or a history of leukopenia/neutropenia and discontinue quetiapine at the first sign of a decline in WBC in absence of other causative factors ( 5.10).
Increased Blood Pressure in Children and Adolescents: Monitor blood pressure at the beginning of, and periodically during treatment in children and adolescents ( 5.9).Hypotension: Use with caution in patients with known cardiovascular or cerebrovascular disease ( 5.7).Tardive Dyskinesia: Discontinue if clinically appropriate ( 5.6).Weight Gain: Gain in body weight has been observed clinical monitoring of weight is recommended.Appropriate clinical monitoring is recommended, including fasting blood lipid testing at the beginning of, and periodically, during treatment. Dyslipidemia: Undesirable alterations have been observed in patients treated with atypical antipsychotics.Monitor glucose regularly in patients with diabetes or at risk for diabetes. Hyperglycemia and Diabetes Mellitus: Monitor patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.These metabolic changes include hyperglycemia, dyslipidemia, and weight gain ( 5.5).Metabolic Changes: Atypical antipsychotics have been associated with metabolic changes.Neuroleptic Malignant Syndrome (NMS): Manage with immediate discontinuation and close monitoring ( 5.4).(e.g., stroke, transient ischemic attack) has been seen in elderly patients with dementia related psychoses treated with atypical antipsychotic drugs ( 5.3).Cerebrovascular Adverse Reactions: Increased incidence of cerebrovascular adverse reactions.
0 kommentar(er)
